Earnings summaries and quarterly performance for BRAINSTORM CELL THERAPEUTICS.
Executive leadership at BRAINSTORM CELL THERAPEUTICS.
Chaim Lebovits
Chief Executive Officer
Alla Patlis
Interim Chief Financial Officer
Hartoun Hartounian
Executive Vice President and Chief Operating Officer
Ibrahim Dagher
Executive Vice President and Chief Medical Officer
Uri Yablonka
Executive Vice President and Chief Business Officer
Board of directors at BRAINSTORM CELL THERAPEUTICS.
Research analysts who have asked questions during BRAINSTORM CELL THERAPEUTICS earnings calls.
David Bautz
Zacks Small Cap Research
4 questions for BCLI
Jason McCarthy
Maxim Group
2 questions for BCLI
Christopher Nicholson
RMB Morgan Stanley
1 question for BCLI
Joanne Lee
Maxim Group
1 question for BCLI
Recent press releases and 8-K filings for BCLI.
- Brainstorm Cell Therapeutics Inc. (BCLI) entered into a promissory note with Auctus Fund, LLC on January 6, 2026, for a principal amount of $140,000.00 and a purchase price of $126,000.00, incurring a 12% one-time interest charge.
- On January 5, 2026, BCLI also secured a convertible promissory note from Quick Capital, LLC with a face amount of $94,875 and an aggregate funded amount of $82,500.
- Additionally, on December 31, 2025, BCLI issued a promissory note to Vanquish Funding Group Inc. for a principal amount of $94,300.00 and a purchase price of $82,000.00, which includes a 12% one-time interest charge and mandatory monthly payments totaling $105,616.00.
- All these notes are convertible into shares of BCLI's common stock. The conversion price is set at 65% of the lowest traded price of the common stock on the Principal Market during the fifteen trading days prior to conversion.
- BrainStorm Cell Therapeutics reported a net loss of $2.1 million for the third quarter ended September 30, 2025, with a net loss per share of $0.19.
- As of September 30, 2025, the company's cash, cash equivalents, and restricted cash were approximately $0.23 million.
- The U.S. FDA has cleared the planned Phase 3b clinical trial of NurOwn, named ENDURANCE, which is expected to enroll approximately 200 participants.
- Research and development expenditures for the third quarter ended September 30, 2025, were $0.9 million, and general and administrative expenses were approximately $1.1 million.
Quarterly earnings call transcripts for BRAINSTORM CELL THERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more